Artiva Biotherapeutics, Inc. balance sheet ARTV

Annual Quarterly

As of Jun 30, 2026, Artiva Biotherapeutics, Inc. had total assets of $368.6 million and total liabilities of $21.1 million. Total assets were up 117.6% from a year earlier. Stockholders' equity was $347.5 million. It held $349.4 million in cash and investments against $9.8 million of total debt, net cash of $339.5 million. The current ratio, current assets divided by current liabilities, was 24.16.

USD in millions, except ratios and per-share amounts. The percent under a figure is the change from the same quarter a year earlier.

Line	Q2 FY2026 Jun 30, 2026	Q1 FY2026 Mar 31, 2026	Q4 FY2025 Dec 31, 2025	Q3 FY2025 Sep 30, 2025	Q2 FY2025 Jun 30, 2025	Q1 FY2025 Mar 31, 2025	Q4 FY2024 Dec 31, 2024	Q3 FY2024 Sep 30, 2024
Assets
Cash	301 +958.9%	21 -31.1%	27 -33.6%	26 -54.4%	28 -16.9%	30	40	56
Short-term investments	48 -57.9%	66 -51.4%	81 -44.0%	97 +7.4%	114 +825.4%	136	145	91
Long-term investments	—	—	—	—	—	—	—	53
Cash and investments	349 +145.4%	87 -47.7%	108 -41.8%	123 -38.4%	142 +205.8%	166	185	200
Receivables	—	—	—	—	—	—	0	1
Total current assets	352 +136.3%	89 -47.8%	113 -40.3%	130 -14.0%	149 +199.6%	170	189	151
Property and equipment, net	6 -17.6%	6 -11.9%	7 +3.9%	7 +1.8%	7 -5.9%	7	6	7
Total assets	369 +117.6%	106 -44.6%	131 -37.5%	149 -34.0%	169 +123.1%	191	210	226
Liabilities and equity
Accounts payable	1 +14.1%	2 +12.3%	0 -68.3%	1 -30.2%	1 +47.6%	2	1	1
Total current liabilities	15 +35.4%	11 -10.8%	13 +6.8%	11 -16.3%	11 -0.5%	12	12	13
Total liabilities	21 +3.8%	18 -19.4%	21 -8.6%	20 -20.2%	20 -59.8%	22	23	25
Stockholders' equity	348 +133.2%	88 -48.0%	110 -41.1%	129 -35.7%	149 +178.0%	169	187	201
Debt
Lease liabilities	10 -25.5%	10 -26.7%	11 -23.5%	12 -21.9%	13 -16.1%	14	14	15
Total debt	10 -25.5%	10 -26.7%	11 -23.5%	12 -21.9%	13 -16.1%	14	14	15
Net cash	340 +162.9%	77 -49.6%	97 -43.3%	111 -39.7%	129 +319.4%	152	171	185
Ratios
Current ratio	24.16x	8.16x	8.61x	11.65x	13.84x	13.93x	15.39x	11.33x
Debt to equity	0.03x	0.12x	0.10x	0.09x	0.09x	0.08x	0.08x	0.07x
Return on equity	-26.14%	-99.12%	-76.26%	-61.28%	-50.41%	—	-35.03%	—
Return on assets	-24.64%	-82.18%	-64.05%	-53.20%	-44.35%	—	-31.19%	—

How these figures are calculated

Quarterly columns are single-quarter amounts. When a 10-Q reports only a year-to-date total, as cash flow statements do, the quarter is that total minus the previous quarter's year-to-date total. The fourth quarter is the annual report's full year minus the first nine months. A column marked YTD is a year-to-date total, shown when the earlier report needed for the single quarter is missing. USD in millions, except ratios and per-share amounts. Cash and investments adds short-term and long-term marketable securities to cash. Debt due within a year is the borrowings that are not already in long-term debt. Total debt is those borrowings plus lease liabilities. Net cash is cash and investments minus total debt. Return on equity and return on assets divide the trailing twelve months of net income by the balance on that date. Debt to EBITDA uses the trailing twelve months of EBITDA. More on our methodology.

Company profile

Industry: Biological Products, (No Diagnostic Substances) (SIC 2836)
Listed as: ARTV (Nasdaq)
Fiscal year ends: December 31
Incorporated in: DE
Headquarters: San Diego, CA
SEC filer status: , Emerging growth company
SEC CIK: 1817241

Other Biological Products, (No Diagnostic Substances) companies

All 182 Biological Products, (No Diagnostic Substances) companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.